Humacyte Inc HUMA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Humacyte Innovative Research in Coronary Bypass and Vascular Regeneration to be Highlighted at American Heart Association Scientific Sessions 2026
Humacyte To Announce 2026 Third Quarter Financial Results and Provide Business Update on November 10, 2026
Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner
Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals
Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months
Trading Information
- Previous Close Price
- $0.40
- Day Range
- $0.40–0.45
- 52-Week Range
- $0.34–1.53
- Bid/Ask
- $0.45 / $0.46
- Shares Outstanding
- 277.80M
- Market Cap
- $124.51M
- Volume/Avg
- 5M / 7M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 41.09
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 184
- Website
- https://www.humacyte.com
Valuation
Metric | HUMA |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.98 |
Price/Sales | 41.09 |
Price/Cash Flow | — |
Price/Earnings
HUMA
Financial Strength
Metric | HUMA |
|---|---|
Quick Ratio | 5.37 |
Current Ratio | 6.21 |
Interest Coverage | −8.57 |
Quick Ratio
HUMA
Profitability
Metric | HUMA |
|---|---|
Return on Assets (Normalized) | −91.49% |
Return on Equity (Normalized) | −1,202.49% |
Return on Invested Capital (Normalized) | −174.89% |
Return on Assets
HUMA
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|FJY@^& | LOCK|ZdxF | $139B | |||
| Moderna Inc MRNA | LOCK|hzwM@^ | LOCK|tD | $103B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|Jw&CSnS | LOCK|GhgC | $94B | |||
| argenx SE ADR ARGX | LOCK|??^FN% | LOCK|B^ | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|LLMtcB | LOCK|mb | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|z&t>W>& | LOCK|sZcV | $30B | |||
| Incyte Corp INCY | LOCK|y$T!yDV | LOCK|>$y | $24B | |||
| BioNTech SE ADR BNTX | LOCK|<Dl!qh> | LOCK|&p | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|>FwJ@Z | LOCK|Pj%^< | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|$$>X#r | LOCK|Wc | $15B |
United States